Certis Oncology announced today that the USPTO has allowed a patent application to Certis’ predictive AI/ML platform, CertisAI™.

Certis Oncology showcased its latest advancements in AI/ML today at the 9th Annual PMWC meeting as part of the event’s coverage of the expanding role of artificial intelligence in precision medicine.

Certis Oncology announces attendance at Tumor Models San Francisco, January 29-30, 2025, and presentation on AI’s role in tumor model characterization data and drug development decision making.

The CertisOI Assistant works as a natural language intermediary for accessing the genomic and drug sensitivity characterization data associated with thousands of cancer research models, including Certis’ patient-derived xenograft (PDX) models as well as public cancer cell lines from the Cancer Cell Line Encycolopedia (CCLE).

CLIA inspections, which are conducted by the Centers for Medicare & Medicaid Services (CMS), are a rigorous process designed to ensure clinical laboratories adhere to strict standards regarding test procedures, equipment, personnel qualifications, and quality control.

At this year’s event, Certis scientists highlighted the applications of the company’s patent-pending, predictive artificial intelligence/machine learning (AI/ML) platform, CertisAI™ for precision medicine and early drug development, and illustrated the importance of using clinically relevant preclinical models when testing cell therapies and researching difficult-to-treat brain cancers.

Certis Oncology Solutions (Certis), a precision oncology and translational science company focused on combining AI-directed drug development with advanced functional testing, today announced that it raised $10 million in a Series C funding round, bringing total raised to $42 million. The company also named John R. Tozzi Chairman of its Board of Directors.

Certis Oncology Solutions (“Certis”), a precision oncology and translational science company focused on combining functional assays and artificial intelligence to advance personalized medicine, today announced the acceptance of an abstract discussing a study evaluating AI-directed combination therapies for the treatment of glioblastoma multiforme (GBM).

Certis Oncology Solutions (Certis), a translational science and precision oncology company, today announced it has been selected as “Overall Immunology Company of the Year” in the third annual BioTech Breakthrough Awards program conducted by BioTech Breakthrough.

Certis Oncology Solutions (“Certis”), a precision oncology and translational science company focused on combining functional assays and artificial intelligence to advance personalized medicine, today announced the acceptance of an abstract for presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting.

ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a next generation biotech, genomics, therapeutics and diagnostics company, today provided an update regarding its progress and development strategy for Linebacker-1 (LB-1), a small molecule, multi-kinase inhibitor.

SOTERIA Precision Medicine Foundation (“SOTERIA”), an organization dedicated to empowering patients, caregivers, and clinicians with the power of precision medicine, today announced a fiscal sponsorship agreement with Certis Oncology Solutions (“Certis”), a San Diego-based precision oncology and translational science company.

In this upcoming live webinar hosted by Xtalks, learn about how artificial intelligence (AI) can bring greater speed and precision to preclinical decision-making. Certis Oncology Solutions Director of Bioinformatics and Data Science Long H. Do, PhD, will discuss the application of multivariate, in silico analyses of protein expression biomarkers and machine learning (ML) algorithms in drug discovery and companion diagnostics (CDx) development.

Certis Oncology Solutions (“Certis”), a precision oncology and translational science company focused on combining functional assays and artificial intelligence (AI) to advance personalized medicine, today announced the launch of CertisAI™, a new predictive medicine platform that utilizes big data, statistical algorithms,and machine learning (ML) to predict drug efficacy based on gene expression biomarkers.

Certis Oncology Solutions (“Certis”), a precision oncology and translational science company focused on combining functional assays and artificial intelligence (AI) to advance personalized medicine, today announced that three abstracts have been accepted for presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting.

In this educational webinar, learn about the latest innovations in preclinical cancer modeling. This talk will cover advancements in patient-derived xenograft (PDX) development, models of spontaneous metastases and other sophisticated approaches to modeling relevant clinical scenarios.

Certis Oncology Solutions, a life science technology company, announced today the release of its new cancer model database, BarneyOI™. This proprietary, online repository houses deep molecular characterization data for Certis’ expanding bank of patient-derived xenograft (PDX) tumor models and cancer cell lines.

Certis Oncology Solutions, a precision oncology and translational science company, announced that it has been awarded accreditation by the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC International).

Certis Oncology Solutions, Inc. has obtained OLAW assurance. Insurance ID: D22-01133.

Certis Oncology Solutions, a precision oncology and translational science company, announced today the favorable conclusion to legal action brought by AntiCancer, Inc., represented by its CEO and owner, Robert Hoffman.

San Diego-based preclinical translational science company is making moves.
Certis Oncology Solutions, Inc., a precision oncology and translational science company, has expanded its operations and moved to a new facility at 5626 Oberlin Drive in San Diego.

Certis Oncology Solutions, a precision oncology and translational sciences company, announced it will make available its personalized approach to drug efficacy testing to the commercial pharmaceutical industry. Industry veteran Debbie Snyder-Stanton has joined the company as Vice President, Pharmaceutical Business Development.

“The best way to get everyone back to living a full life — including enjoying live performances — is through more and more accurate testing,” Peter Ellman, CEO of Certis Oncology Solutions, said in a statement. “We applaud Mainly Mozart for finding creative ways to bring people together and are sincerely pleased to play this role in ensuring the musicians’ safety.”

Certis Oncology Solutions, a clinical research organization (CRO) and precision cancer therapy company, announced today it is offering mobile COVID-19 testing services to area businesses.